Table 2.
Number of patients, and long-term outcomes.
| Author | Year | Patients | Completion TME in LE | Follow-Up | Local Regrowth | Local Recurrence | Distant Recurrence | Organ Preservation |
Disease-Free Survival (DFS) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WW | LE | Required/Performed | WW | LE | WW | LE | WW | LE | WW | LE | ||||
| Vaccaro | 2016 | 23 | 7 | 0/0 | 46 | 4 (18.5) | 0 (0) | 1 (4.3) | 1 (14.3) | 21 (91) | 7 (100) | 3-year 94.1% | ||
| Creavin | 2016 | 10 | 50 | 15/15 | 42 | 29 | 1 (10) | 3 (6) | 1 (10) | 5 (10) | 9 (90) | 33 (66) | 80% | 80% |
| Asoglu | 2019 | 39 | 6 | 0/0 | 22 | 6 (15.4) | 1 (16.6) | 2 (5.1) | 1 (16.6) | 36 (92.3) | 5 (83.3) | |||
| Park | 2019 | 32 | 42 | 11/0 | 73 | 65 | 10 (31.3) | 2 (4.8) | 1 (3.1) | 4 (9.5) | 27 (84.3) | 42 (100) | 5-year RFS 69.8% | 5-year RFS 84.6% |
| Yeom | 2019 | 15 | 25 | NR | 20 | 30 | 4 (26.7) | 4 (16) | 5 (33.3) | 6 (24) | 14 (93.3) | 23 (92.0) | 3-year DFS 72.9% | 3-year DFS 55.5% |
| Al-Najami | 2021 | 42 | 22 | 16/3 | 53 | 11 (26) | 10 (45) | 4 (18.2) | 38 (95) | 16 (73) | 3-year 66.2% | |||
| Lee | 2021 | 14 | 30 | 64.7 | 3 (21.4) | 4 (13.3) | 0 (0) | 2 (6.7) | 12 (85.7) | 27 (90) | 5-year DFS 76.4% | |||
| Wang | 2022 | 38 | 6 | 0/0 | 39.5 | 7 (18.4) | 0 (0) | 2 (5.3) | 1 (16.7) | 33 (86.8) | 6 (100) | |||